Want to see GB:VRCI full AI Analyst Report?
VRCI Stock Chart & Stats
0.35 p
0.00 p(0.00%)
At close: 4:00 PM EDT
0.35 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.20 p - 0.99 p
Previous CloseN/A
Volume504.48K
Average Volume (3M)6.85M
Market Cap
£5.72M
Enterprise Value8.63 p
Total Cash (Recent Filing)£3.34M
Total Debt (Recent Filing)£197.07K
Price to Earnings (P/E)―
Beta-1.47
Next Earnings
Sep 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding2,287,311,300
10 Day Avg. Volume9,044,876
30 Day Avg. Volume6,845,005
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.20
Price to Sales (P/S)2.08
P/FCF Ratio-0.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.90M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapid revenue expansion indicates increasing adoption of Verici Dx’s transplant diagnostics and improving commercial traction. Sustained growth could strengthen operating leverage and support broader distribution, although profitability remains unproven.
Positive Gross ProfitPositive and rising gross profit suggests the tests generate economic value above direct delivery costs. If adoption continues, this provides a foundation for future margin expansion as fixed commercial and development costs are spread over higher volumes.
Low LeverageLow and declining debt reduces interest and refinancing pressure relative to a highly leveraged business. Positive equity preserves some financial flexibility, although continued losses and cash consumption could require additional funding.
Bears Say
Persistent Net LossesDeepening net losses show that revenue growth has not yet translated into a sustainable operating model. Continued losses may delay self-funding, constrain investment capacity, and increase the risk of shareholder dilution if external capital is needed.
Worsening Cash BurnPersistently negative operating and free cash flow indicates the business consumes substantial cash to operate and grow. The worsening 2025 burn increases dependence on financing and makes execution of the commercialization strategy financially more demanding.
Shrinking Asset BaseA shrinking asset base alongside ongoing losses signals reduced financial resources and potential value erosion. If cash generation does not improve, Verici Dx may need new capital to maintain development and commercialization, creating funding and dilution risk.
Verici Dx Plc News
VRCI FAQ
What was Verici Dx Plc’s price range in the past 12 months?
Verici Dx Plc lowest share price was 0.20 p and its highest was 0.99 p in the past 12 months.
What is Verici Dx Plc’s market cap?
Verici Dx Plc’s market cap is £5.72M.
When is Verici Dx Plc’s upcoming earnings report date?
Verici Dx Plc’s upcoming earnings report date is Sep 14, 2026 which is in 27 days.
How were Verici Dx Plc’s earnings last quarter?
Verici Dx Plc released its earnings results on Jun 29, 2026. The company reported -0.002 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Verici Dx Plc overvalued?
According to Wall Street analysts Verici Dx Plc’s price is currently Overvalued.
Does Verici Dx Plc pay dividends?
Verici Dx Plc does not currently pay dividends.
What is Verici Dx Plc’s EPS estimate?
Verici Dx Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Verici Dx Plc have?
Verici Dx Plc has 2,287,311,300 shares outstanding.
What happened to Verici Dx Plc’s price movement after its last earnings report?
Verici Dx Plc reported an EPS of -0.002 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Verici Dx Plc?
Currently, no hedge funds are holding shares in GB:VRCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Verici Dx Plc
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Renalytix
―
Abingdon Health PLC
―